Welcome to EiRx Therapeutics

EiRx Therapeutics plc (LSE: ERX) is a research-driven healthcare company developing new targeted therapies for the treatment of cancer. The company, which is headquartered in Cork, Ireland, conducts drug discovery from its laboratories in Cork and in Aberdeen, Scotland, and has an initial focus on treatment of colorectal and breast cancers.

Since its foundation in 1999 EiRx has developed a leading expertise in the study of functional pathways critical to cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. Using its state-of-the-art, proprietary ALIBI™ platform, EiRx has gained new insights into the mechanisms underlying a cell's decision to survive or die, and has implicated a range of novel genes in pivotal control mechanisms such as the PI3K/AKT and APC / β-catenin survival pathways. By combining functional validation technologies with unique clinical resources such as the ACCRI-BANK tissue collection, EiRx is linking the molecular activity of these targets with clinical consequences in patient populations. By streaming validated targets into an innovative, pathway-targeting compound screening approach EiRx is creating a product development engine specialising in cancer target discovery, validation and targeted therapy.

Next: About EiRx »
Site Last Updated: 11.04.08